Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA approves Lisraya for dermatomyositis in adults

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicalxpress.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

The U.S. FDA has approved Lisraya (brepocitinib) as the first oral treatment for dermatomyositis in adults, based on a phase 3 trial showing improved clinical response and reduced corticosteroid use.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.

◆ ◆ The Wire takeaway

You now face a new market opportunity as Lisraya sets a precedent for oral dermatomyositis treatments in the US. Pharma founders should fast-track oral drug development to meet evolving patient and provider expectations.

◆ Coverage

10 sources · first reported 27 Aug 2026 · latest 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaldermatomyositisoral-treatmentbiotechpharma